Disappointing news on Bristol-Myers Squibb’s immunotherapy combo medication has the stock down to new lows today.
This is their Opdivo drug treatment for lung cancer. This drug has been in the news before and sunk the stock last year on results as well.
The news that in trials those with lung cancer saw a reduction of death rates by 42% is not high enough in relation to Merck’s results from their drug Keytruda which showed a significantly better death rate reduction.
Already down over 8%, another pharmaceutical company, Merck is watching it’s stock soar higher today. Let’s take a look at both companies and review some of the trades done today to see which stock might be better in a portfolio.
The rest of this trade alert and ideas article is for FullyInformed Members.
Bristol-Myers Squibb Stock (BMY) VS Merck Stock (MRK) – Apr 16 2018
Disclaimer: There are risks involved in all investment strategies and investors can and do lose capital. Trade at your own risk. Stocks, options and investing are risky and can result in considerable losses. None of the strategies, stocks or information discussed and presented are financial or trading advice or recommendations. Everything presented and discussed are the author’s own trade ideas and opinions which the author may or may not enter into. The author assumes no liability for topics, ideas, errors, omissions, content and external links and trades done or not done. The author may or may not enter the trades mentioned. Some positions in mentioned stocks may already be held or are being adjusted.